Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE

Abstract Introduction Although acute and preventive treatments for migraine are commonly given in combination, data on the real-world effectiveness of ubrogepant as an acute treatment when used with an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (with or without onabotulinumtoxin...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Richard B. Lipton, Janette Contreras-De Lama, Daniel Serrano, Ella Engstrom, Nicolai D. Ayasse, Weijie Poh, François Cadiou, Aubrey Manack Adams
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2023-11-01
Edice:	Neurology and Therapy
Témata:	CGRP Effectiveness Migraine Real-world Satisfaction Ubrogepant
On-line přístup:	https://doi.org/10.1007/s40120-023-00556-8
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!